Safely Enhancing Drug Delivery to the CNS

An Innovative Platform Technology

Sijme Zeilemaker, MScBusiness Development Associateto-BBB

Science meets BusinessSeptember 2013

Background

2005 – 2011 Biomedical Sciences at Leiden University

2008: LACDR internship

Master Biomedical Sciences – Management

Science Based Business

2010: Business Internship

A start-up company in neuroscience…

Blood-Brain Barrier

600 kilometer

Every neuron has its own capillary

• G-Technology®: safe brain delivery technology• Glutathione: safe brain targeting mechanism • PEG-liposomes: well-established delivery technology• Strong patent protection on any drug combination

to-BBB’s brain drug delivery platform

G-Technology: mechanistic validation in vitro

5 times more in brain improved anti-cancer effect

G-Technology: mechanistic validation in vivo

Doxil/Caelyx: PEG liposomal doxorubicin2B3-101: Glutathione-PEG liposomal doxorubicin

2B3-101: confirming the safe brain delivery platform

Lead product 2B3-101 treating patients with brain cancer•Therapeutic dosages reached with a predictable safety profile

•Favorable long circulation plasma half-life of 64 hours

•Early signs of clinical efficacy with partial responses and stable disease

•Results to be presented at European Cancer Congress, Amsterdam

2-fold business model: internal development

Enhanced uptake across CNS•Safe, endogenous mechanism

Increased half life•Reduce dosing frequency

Liposomal shielding•Reduce side effects

Strong IP protection•Life Cycle Management

2-fold business model: pharma/biotech partnering

this could be your compound!

Business Development: all about partnering

Pharma*:

Mid-size pharma / biotech*:

Grants:

*examples

Business Development: getting done more… with less

Pharma*:

Mid-size pharma / biotech*:

Grants:

*examples

build a leading company in brain drug development

build a leading company in brain drug development